116 related articles for article (PubMed ID: 12664053)
41. Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: similar clinical results and minor biochemical differences.
Wimmer-Greinecker G; Matheis G; Martens S; Oremek G; Abdel-Rahman U; Moritz A
Eur J Cardiothorac Surg; 1999 Aug; 16(2):211-7. PubMed ID: 10485423
[TBL] [Abstract][Full Text] [Related]
42. Heparin-coated cardiopulmonary bypass circuits reduce blood cell trauma. Experiments in the pig.
Thelin S; Bagge L; Hultman J; Borowiec J; Nilsson L; Thorelius J
Eur J Cardiothorac Surg; 1991; 5(9):486-91. PubMed ID: 1931093
[TBL] [Abstract][Full Text] [Related]
43. A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit.
Palatianos GM; Foroulis CN; Vassili MI; Astras G; Triantafillou K; Papadakis E; Lidoriki AA; Iliopoulou E; Melissari EN
Ann Thorac Surg; 2003 Jul; 76(1):129-35. PubMed ID: 12842526
[TBL] [Abstract][Full Text] [Related]
44. Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface.
Johnell M; Elgue G; Larsson R; Larsson A; Thelin S; Siegbahn A
J Thorac Cardiovasc Surg; 2002 Aug; 124(2):321-32. PubMed ID: 12167793
[TBL] [Abstract][Full Text] [Related]
45. Changes in blood coagulation during and following cardiopulmonary bypass: lack of correlation with clinical bleeding.
Gelb AB; Roth RI; Levin J; London MJ; Noall RA; Hauck WW; Cloutier M; Verrier E; Mangano DT
Am J Clin Pathol; 1996 Jul; 106(1):87-99. PubMed ID: 8701939
[TBL] [Abstract][Full Text] [Related]
46. Low-dose and high-dose aprotinin improve hemostasis in coronary operations.
Speekenbrink RG; Wildevuur CR; Sturk A; Eijsman L
J Thorac Cardiovasc Surg; 1996 Aug; 112(2):523-30. PubMed ID: 8751522
[TBL] [Abstract][Full Text] [Related]
47. The influence of the duration of cardiopulmonary bypass on coagulation, fibrinolysis and platelet function.
Wahba A; Rothe G; Lodes H; Barlage S; Schmitz G
Thorac Cardiovasc Surg; 2001 Jun; 49(3):153-6. PubMed ID: 11432473
[TBL] [Abstract][Full Text] [Related]
48. Infusion of autologous platelet rich plasma does not reduce blood loss and product use after coronary artery bypass. A prospective, randomized, blinded study.
Tobe CE; Vocelka C; Sepulvada R; Gillis B; Nessly M; Verrier ED; Hofer BO
J Thorac Cardiovasc Surg; 1993 Jun; 105(6):1007-13; discussion 1013-4. PubMed ID: 8501929
[TBL] [Abstract][Full Text] [Related]
49. Cardiotomy suction, but not open venous reservoirs, activates coagulofibrinolysis in coronary artery surgery.
Nakahira A; Sasaki Y; Hirai H; Matsuo M; Morisaki A; Suehiro S; Shibata T
J Thorac Cardiovasc Surg; 2011 May; 141(5):1289-97. PubMed ID: 20800241
[TBL] [Abstract][Full Text] [Related]
50. The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery.
Kuitunen A; Hiippala S; Vahtera E; Rasi V; Salmenperä M
Acta Anaesthesiol Scand; 2005 Oct; 49(9):1272-9. PubMed ID: 16146463
[TBL] [Abstract][Full Text] [Related]
51. Influence of high- and low-dose aprotinin on activation of hemostasis in open heart operations.
Dietrich W; Schöpf K; Spannagl M; Jochum M; Braun SL; Meisner H
Ann Thorac Surg; 1998 Jan; 65(1):70-7; discussion 77-8. PubMed ID: 9456098
[TBL] [Abstract][Full Text] [Related]
52. A comparison of haemostatic biomarkers during low-risk patients undergoing cardiopulmonary bypass using either conventional centrifugal cell salvage or the HemoSep device.
Boyle G; Kuffel A; Parmar K; Gibson K; Smith M; Grehan A; Hunt BJ; Chambers DJ
Perfusion; 2019 Jan; 34(1):76-83. PubMed ID: 30067140
[TBL] [Abstract][Full Text] [Related]
53. Reduction of blood activation in patients receiving aprotinin during cardiopulmonary bypass for coronary artery surgery.
Baufreton C; Velthuis HT; Jansen PG; Besnerais PL; Wildevuur CH; Loisance DY
ASAIO J; 1996; 42(5):M417-23. PubMed ID: 8944919
[TBL] [Abstract][Full Text] [Related]
54. Hemostasis in off-pump compared to on-pump coronary artery bypass grafting: a prospective, randomized study.
Vedin J; Antovic A; Ericsson A; Vaage J
Ann Thorac Surg; 2005 Aug; 80(2):586-93. PubMed ID: 16039210
[TBL] [Abstract][Full Text] [Related]
55. A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system.
Rossi M; Storti S; Martinelli L; Varano C; Marra R; Zamparelli R; Possati G; Schiavello R
J Cardiothorac Vasc Anesth; 1997 Dec; 11(7):835-9. PubMed ID: 9412880
[TBL] [Abstract][Full Text] [Related]
56. Heparin-coated versus uncoated extracorporeal circuit in patients undergoing coronary artery bypass graft surgery.
Oliver WC; Nuttall GA; Ereth MH; Santrach PJ; Buda DA; Schaff HV
J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):165-70. PubMed ID: 12698396
[TBL] [Abstract][Full Text] [Related]
57. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
[TBL] [Abstract][Full Text] [Related]
58. A clinical, renal and immunological assessment of surface modifying additive treated (SMART) cardiopulmonary bypass circuits.
Allen S; McBride WT; Young IS; MacGowan SW; McMurray TJ; Prabhu S; Penugonda SP; Armstrong MA
Perfusion; 2005 Sep; 20(5):255-62. PubMed ID: 16231621
[TBL] [Abstract][Full Text] [Related]
59. Early platelet recovery following cardiac surgery with cardiopulmonary bypass.
Van Poucke S; Stevens K; Wetzels R; Kicken C; Verhezen P; Theunissen M; Kuiper G; van Oerle R; Henskens Y; Lancé M
Platelets; 2016 Dec; 27(8):751-757. PubMed ID: 27164510
[TBL] [Abstract][Full Text] [Related]
60. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
